Q3 Earnings Forecast for Jade Biosciences Issued By Wedbush

Key Points

• Wedbush has lowered its Q3 2025 earnings per share (EPS) forecast for Jade Biosciences to ($0.72), down from a previous estimate of ($0.43).
• The company's last quarterly earnings report showed a miss with an EPS of ($0.86), compared to a consensus estimate of ($0.43).
• Jade Biosciences' current stock price is $9.40, with a market capitalization of approximately $306.72 million.

Jade Biosciences, Inc. (NASDAQ:JBIO - Free Report) - Research analysts at Wedbush cut their Q3 2025 EPS estimates for Jade Biosciences in a note issued to investors on Wednesday, October 8th. Wedbush analyst L. Chico now anticipates that the company will earn ($0.72) per share for the quarter, down from their prior forecast of ($0.43). Wedbush has a "Outperform" rating and a $18.00 price target on the stock. Wedbush also issued estimates for Jade Biosciences' Q4 2025 earnings at ($0.58) EPS, FY2025 earnings at ($4.62) EPS, Q1 2026 earnings at ($0.51) EPS, Q2 2026 earnings at ($0.53) EPS, Q3 2026 earnings at ($0.44) EPS, Q4 2026 earnings at ($0.46) EPS and FY2026 earnings at ($1.92) EPS.

Jade Biosciences (NASDAQ:JBIO - Get Free Report) last released its quarterly earnings results on Wednesday, August 13th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.43).

A number of other equities analysts also recently weighed in on JBIO. Jefferies Financial Group initiated coverage on shares of Jade Biosciences in a research note on Monday, July 14th. They set a "buy" rating and a $16.00 target price for the company. Wall Street Zen downgraded shares of Jade Biosciences from a "hold" rating to a "sell" rating in a research note on Saturday, August 16th. Guggenheim raised shares of Jade Biosciences from a "neutral" rating to a "buy" rating and set a $14.00 target price for the company in a research note on Monday, June 16th. BTIG Research initiated coverage on shares of Jade Biosciences in a research note on Thursday. They set a "buy" rating and a $28.00 target price for the company. Finally, Weiss Ratings reaffirmed a "sell (e-)" rating on shares of Jade Biosciences in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $19.00.

Jade Biosciences Stock Up 3.5%

Shares of NASDAQ JBIO opened at $9.40 on Friday. Jade Biosciences has a fifty-two week low of $6.57 and a fifty-two week high of $105.00. The firm's 50 day simple moving average is $7.83. The company has a market capitalization of $306.72 million, a P/E ratio of -0.31 and a beta of 1.05.

Institutional Investors Weigh In On Jade Biosciences

A number of institutional investors have recently made changes to their positions in JBIO. Frazier Life Sciences Management L.P. purchased a new stake in shares of Jade Biosciences during the second quarter valued at approximately $17,703,000. Versant Venture Management LLC purchased a new stake in Jade Biosciences in the second quarter worth approximately $15,243,000. Soleus Capital Management L.P. purchased a new stake in Jade Biosciences in the second quarter worth approximately $7,959,000. Geode Capital Management LLC purchased a new stake in Jade Biosciences in the second quarter worth approximately $6,759,000. Finally, Orbimed Advisors LLC purchased a new stake in Jade Biosciences in the second quarter worth approximately $5,306,000.

About Jade Biosciences

Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.